1. Monoclonal antibody fragment from combinatorial phage display library neutralizes alpha-latrotoxin activity and abolishes black widow spider venom lethality, in mice
- Author
-
Enzo Ricci, Francesco Paroni Sterbini, Stefano Rufini, Riccardo Torelli, Francesca Bugli, Giovanni Fadda, Alfonso Grasso, Rosalia Graffeo, Luca Masucci, Mario Pescatori, and Michela Sali
- Subjects
Phage display ,medicine.drug_class ,Latrotoxin ,Spider Venoms ,Venom ,Biology ,Toxicology ,Monoclonal antibody ,Settore BIO/09 ,Antibodies ,Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA ,Mice ,Peptide Library ,In vivo ,Monoclonal ,medicine ,Latrodectism ,Animals ,Inbred BALB C ,Mice, Inbred BALB C ,Antibodies, Monoclonal ,medicine.disease ,Molecular biology ,Recombinant Proteins ,Female ,Gene Expression Regulation ,Protein Binding ,biology.protein ,Antibody - Abstract
Alpha-latrotoxin (alpha-ltx), a component of the venom of black widow spiders (BWSV), binds to higher vertebrates presynaptic nerve terminals, stimulating massive neurotransmitter release. This neurotoxic protein is responsible for most of the symptoms elicited in men by the bite of black widow spider (BWS), i.e. a neurological syndrome named latrodectism. By reasoning that targeting this single component would abrogate most of the effect of BWS envenomation, we took advantage of the antibody phage display technology to generate monoclonal Fab fragments able to bind and neutralize the alpha-ltx. To this aim, we immunized Balb/c mice with purified toxin and cloned their antibody repertoire in the pCombIII phage display vector. By combining a high-stringency affinity selection with a sensitive 45Ca(2+) uptake assay, we isolated a Fab fragment (FM1) able to bind the alpha-ltx in the low nM range and neutralize its ionophore activity, in vitro and in vivo. After the onset of overt symptomatology, administration of FM1 to experimentally envenomed mice induced remission of symptoms and prevented lethality. Since alpha-ltx is the only molecule responsible for the great toxicity of BWS bites in mammals, the FM1 Fab, highly effective in neutralizing the toxin in vivo, represents a promising immunotherapy reagent for treating latrodectic patients.
- Published
- 2008
- Full Text
- View/download PDF